Nothing Special   »   [go: up one dir, main page]

Adamczyk-Popławska et al., 2020 - Google Patents

Covid-19 therapy: What have we learned in 8 months?

Adamczyk-Popławska et al., 2020

View PDF
Document ID
345863349486339434
Author
Adamczyk-Popławska M
Kwiatek A
Publication year
Publication venue
Advancements of Microbiology

External Links

Snippet

SARS-CoV-2, a novel pathogenic human coronavirus, emerged in December of 2019 in Wuhan (Hubei province, China). In most cases, the infection causes a mild to moderate respiratory illness. However, a undefined group of infected may develop a severe or critical …
Continue reading at sciendo.com (PDF) (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Micro-organisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages

Similar Documents

Publication Publication Date Title
Yang Application of nanotechnology in the COVID-19 pandemic
Santos et al. Antivirals against coronaviruses: candidate drugs for SARS-CoV-2 treatment?
Lopes-Pacheco et al. Pathogenesis of multiple organ injury in COVID-19 and potential therapeutic strategies
Fung et al. Similarities and dissimilarities of COVID-19 and other coronavirus diseases
Kaddoura et al. COVID-19 therapeutic options under investigation
Xia et al. Middle East respiratory syndrome coronavirus (MERS-CoV) entry inhibitors targeting spike protein
Ahidjo et al. Current perspective of antiviral strategies against COVID-19
Das et al. An overview of key potential therapeutic strategies for combat in the COVID-19 battle
Kumar et al. The chronicle of COVID-19 and possible strategies to curb the pandemic
Yaghoubi et al. An effective drug against COVID-19: reality or dream?
Ohadian Moghadam A review on currently available potential therapeutic options for COVID-19
Hossain et al. Understanding and dealing the SARS-CoV-2 infection: an updated concise review
Kaur et al. A comprehensive review on epidemiology, aetiopathogenesis, diagnosis and treatment of the novel coronavirus syndrome–COVID-19
Patil et al. Emergence, transmission, and potential therapeutic targets for the COVID-19 pandemic associated with the SARS-CoV-2
Adamczyk-Popławska et al. Covid-19 therapy: What have we learned in 8 months?
Dubey et al. Race to arsenal COVID-19 therapeutics: Current alarming status and future directions
Pal et al. Current updates on adaptive immune response by B cell and T cell stimulation and therapeutic strategies for novel coronavirus disease 2019 (COVID-19) treatment
Unal et al. COVID 19 disease caused by Coronavirus 2 (SARS-CoV-2)(severe acute respiratory syndrome)
Kangarshahi et al. THE PROTEINS OF SARS-CoV-2 AND THEIR FUNCTIONS.
Nomier et al. Distinctive Therapeutic Strategies against Corona Virus19 (COVID-19): A Pharmacological Review.
Sabarimurugan et al. Comprehensive review on the prevailing COVID-19 therapeutics and the potential of repurposing SARS-CoV-1 candidate drugs to target SARS-CoV-2 as a fast-track treatment and prevention option
Michalski et al. Review of studies on SARS-CoV-2 infection inhibitors
Onwudiwe et al. Pharmacological treatment of COVID-19: an update
Akilesh et al. Repositioning of drugs to counter COVID-19 pandemic-An Insight
Luo et al. Combination therapies against COVID-19